Apellis Pharmaceuticals Inc (APLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Apellis Pharmaceuticals Inc (APLS) has a cash flow conversion efficiency ratio of -0.147x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-60.97 Million) by net assets ($414.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Apellis Pharmaceuticals Inc balance sheet quality to measure how much of total assets are equity-financed.
Apellis Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Apellis Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Apellis Pharmaceuticals Inc (APLS) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Apellis Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apellis Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Banestes S.A - Banco do Estado do Espírito Santo
SA:BEES3
|
-1.747x |
|
Gruvaktiebolaget Viscaria
ST:VISC
|
-0.018x |
|
Sinosun Tech
SHE:300333
|
-0.011x |
|
Actron Technology
TWO:8255
|
0.046x |
|
Yuanbao Inc. American Depositary Shares
NASDAQ:YB
|
0.399x |
|
Dingli Communications Corp Ltd
SHE:300050
|
0.082x |
|
AdvanSix Inc
NYSE:ASIX
|
0.032x |
|
Fenix Outdoor International AG
ST:FOI-B
|
-0.029x |
Annual Cash Flow Conversion Efficiency for Apellis Pharmaceuticals Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Apellis Pharmaceuticals Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Apellis Pharmaceuticals Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $370.15 Million | $45.33 Million | 0.122x | +131.85% |
| 2024-12-31 | $228.54 Million | $-87.87 Million | -0.384x | +87.43% |
| 2023-12-31 | $194.52 Million | $-594.74 Million | -3.057x | -1.10% |
| 2022-12-31 | $169.87 Million | $-513.75 Million | -3.024x | -6.69% |
| 2021-12-31 | $198.66 Million | $-563.13 Million | -2.835x | -261.30% |
| 2020-12-31 | $204.56 Million | $-160.49 Million | -0.785x | +87.28% |
| 2019-12-31 | $34.23 Million | $-211.13 Million | -6.168x | -656.56% |
| 2018-12-31 | $160.97 Million | $-131.24 Million | -0.815x | -160.61% |
| 2017-12-31 | $148.94 Million | $-46.60 Million | -0.313x | +71.37% |
| 2016-12-31 | $23.79 Million | $-26.00 Million | -1.093x | -102.71% |
| 2015-12-31 | $34.98 Million | $-18.86 Million | -0.539x | +28.33% |
| 2014-12-31 | $13.22 Million | $-9.95 Million | -0.752x | +1.25% |
| 2013-12-31 | $4.52 Million | $-3.44 Million | -0.762x | -- |
About Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy… Read more